BGI Genomics (300676) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

300676 BGI Genomics

Watchlist

46.50
-0.88-1.86%

Market Closed Dec 13 15:00 CST

19.34BMarket Cap-190.57P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Analysis and Forecast Report 2024, With Focus on BGI Genomics and Annoroad Gene Technology
Yahoo FinanceDec 6 04:31 ET
A model of the integration of precision medical and technology, bgi genomics (300676.SZ) received the "Annual Excellence Award for Health Enterprises."
Health is not only the cornerstone of personal quality of life but also an important factor for social stability and economic development. Nowadays, with the improvement of living standards and increased health awareness, people's attention to health issues has reached unprecedented heights. In the face of this global trend, many enterprises have invested in the big health industry, committed to improving the quality and efficiency of medical services through technological innovation to meet the growing health demands. In this context, bgi genomics (300676.SZ) has excelled in the deep integration of technological innovation and precision medical, at the recent "9th Glorious Gathering Global".
Gelonghui FinanceDec 6 00:06 ET
Japan Non-Invasive Prenatal Testing Market Size, Trends, Growth and Forecasts 2024-2032 With Competitive Analysis of SR, BGI Genomics, Macrogen Japan, and LSI Medience - ResearchAndMarkets.com
BusinesswireNov 25 12:35 ET
Health Check: How Prudently Does BGI Genomics (SZSE:300676) Use Debt?
Simply Wall StNov 17 19:17 ET
Asia-Pacific Metagenomics Market Research 2024-2033 With Competitive Analysis of Leading Players - BGI Genomics, MGI Tech, and Macrogen - ResearchAndMarkets.com
BusinesswireNov 8 07:51 ET
BGI: Report for the third quarter of 2024
SZSIOct 25 12:00 ET · Announcements

Comments

Moomoo AI

Feb 21 16:26

BGI Genomics' low ROE and net income growth are worrisome. Despite high reinvestment, the low ROE indicates that it's not benefiting investors and is hampering earnings growth. Caution is advised due to these factors.

Are BGI Genomics Co., Ltd.'s (SZSE:300676) Mixed Financials Driving The Negative Sentiment?

Spinee

Jan 28 19:47

A bill to prohibit contracting with certain biotechnology providers, and for other purposes.

BGI, MGI, Complete Genomics, Wuxi Apptec, and any subsidiary are included.
Last Friday, WuXi AppTec's shares tumble by 20% in Hong Kong and fall by a 10% limit-down in mainland China.
Other CRO stocks including Medicilon are also falling.
$WUXI BIO (02269.HK)$ $WUXI APPTEC (02359.HK)$ $BGI Genomics (300676.SZ)$ $MGI Tech Co., Ltd. (688114.SH)$ $Shanghai Medicilon Inc. (688202.SH)$ $Novo-Nordisk A/S (NVO.US)$ $Hang Seng H-Share Index ETF (02828.HK)$

Moomoo AI

Jan 24 18:28

Despite a significant drop in BGI Genomics' EPS and share price, the market still sees a promising future, as indicated by its high P/E ratio. Investors should monitor the company's fundamentals and be vigilant for warning signs.

Investors in BGI Genomics (SZSE:300676) Have Unfortunately Lost 73% Over the Last Three Years

Moomoo AI

Jan 1 19:19

Investors currently view BGI Genomics as an underperforming company, largely influenced by its poor revenue growth over the past years. Its P/S ratio may tumble further if the company fails to improve its revenue growth, leading to further investor disappointment.

Improved Revenues Required Before BGI Genomics Co., Ltd. (SZSE:300676) Shares Find Their Feet

Moomoo AI

Nov 20, 2023 17:32

BGI Genomics' low ROE and limited earnings growth, despite high profit retention, raise concerns about its financial performance and efficient use of equity capital and profits. The current price momentum may not be sustainable.